Indeed, PARPi in combination with STING agonists demonstrated superior anti-tumor efficacy than PARPi combined with macrophage depletion via anti-CSF1R in our syngeneic GEMM of Brca1-deficient breast cancers. This evidence concerns the gene BRCA1 and breast carcinoma.